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In principle, accurate guideline recommendations should lead to optimal management based on a secure
diagnosis. However, current IPF diagnostic guidelines do not meet the needs of a major sub-group (possibly the
majority) of patients with idiopathic pulmonary fibrosis (IPF). A great many IPF patients have HRCT appearances of
“possible UIP”. A surgical biopsy is very often impracticable due to age, disease severity, co-morbidities or patient
refusal. A guideline-based diagnosis cannot be made in these patients, although the diagnosis is often obvious.
Inflexible diagnostic criteria, although essential for treatment trials, must necessarily be structured around an
inflexible diagnostic algorithm. With this approach, non-standardised information (i.e. not available in all patients)
must be omitted, including observed disease behaviour prior to and on treatment, findings on bronchoalveolar
lavage, likelihoods in relation to age and a wealth of ancillary clinical information. However, when a diagnosis
cannot be made using guideline criteria, a probable or highly probable “working diagnosis” of IPF can and should
be made in most IPF patients by means of clinical reasoning, integrating all available non-standardised information.
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Background
Idiopathic pulmonary fibrosis (IPF), the most progressive
and most prevalent of the idiopathic interstitial pneumo-
nias (IIPs), requires a radically different management
from the other IIPs due to its prognostic implications
and the advent of IPF-specific therapies. With regards
to their management, the remaining IIPs can largely
be conceptualised as forms of immune dysregulation;
however, this model has failed in IPF [1].
It might be supposed that the accurate diagnosis of
IPF should depend upon the application of evidence-
based diagnostic guidelines. Yet, in at least half of IPF
patients, the diagnosis cannot be made using current
American Thoracic Society/European Respiratory Society/
Japanese Respiratory Society/Latin America Thoracic
Association (ATS/ERS/JRS/ALAT) guideline criteria [2].
The ‘failsafe option’ of a surgical biopsy, recommended
when the diagnosis cannot be made non-invasively, ap-
plies to perhaps 15 % of patients in this setting given
the average age of onset, severity of disease at presen-
tation, comorbidities and, importantly, the disinclination
of patients to undergo a procedure with a mortality rate of
3–6 % [3, 4]. It is possible that cryobiopsy techniques will
make a major difference [5], but only time will tell.
Currently, in roughly half of IPF patients, ATS/ERS/JRS/
ALAT 2011 diagnostic criteria for IPF are not satisfied
and the disease remains unclassifiable. In this setting,
clinicians must speculate on the best course of action –
whether to manage the disease according to a diagnosis of
alternative disorders or to apply IPF-validated anti-fibrotic
therapies. In a nutshell, the ATS/ERS/JRS/ALAT 2011 IPF
diagnostic guidelines are ‘broken’.
How has it come to this? The pace of recent events is
partly to blame. In 2009/2010, when the ATS/ERS/JRS/
ALAT guidelines were formulated, there was no univer-
sally accepted therapy known to delay disease progres-
sion and it was generally agreed that best management
consisted of participation in a novel treatment trial [2].
Rigorous diagnostic criteria are required in drug trials.
However, and perhaps more importantly, a treatment
option, in the form of triple therapy with low dose pred-
nisolone, azathioprine, and N-acetyl cysteine [6], was
available. This option could, until recently, reasonably be
applied equally in IPF or in the realistic differential diag-
noses in which immune dysregulation is thought to play
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a primary pathogenetic role. Thus, the ATS/ERS/JRS/
ALAT 2011 guidelines provided appropriate diagnostic
rigour for trial purposes and, at that time, it could be
argued that patients disenfranchised by IPF diagnostic
criteria were not disadvantaged for practical manage-
ment purposes. Perhaps it was not possible in 2011 to
do better than this. However, everything changed irrev-
ocably when IPF-specific therapies were validated, and
particularly when it became apparent, from the findings
in the PANTHER study, that triple therapy should not
be used in IPF [7]. For the first time, diagnosis became
pivotal in clinical practice, as opposed to the confines of
drug trials. PANTHER was the final clause in the desta-
bilisation of the 2011 IPF diagnostic guidelines.
Nevertheless, recent events are only partly to blame.
There is a second issue related to the decline and fall of
‘eminence-based medicine’. Fortunately, the age of the
opinion hegemony – a handful of experts driving best
medical practice based on their anecdotal views – is
over. However, we have fallen into a new and equally
damaging trap – the belief that logic and common sense
must be discarded and only data formalised within an
‘evidence base’ can be taken into account. It may seem
surprising that the Evidence-based Renaissance Group
recently published a perspective entitled, Evidence-based
Medicine, a Movement in Crisis [8]. However, by defin-
ition, the rigid application of an evidence base is founded
on the assumption that ‘one size fits all’. Sometimes, this
approach is essential – in the evaluation of expensive
treatments which may have serious side effects, a rigorous
question must be asked using stringent methods. How-
ever, in other contexts, an evidence-based tyranny can
actually be harmful, as, for example, in the multidisciplin-
ary diagnosis of IPF.
Whatever else is said about the ATS/ERS/JRS/ALAT
2011 IPF guidelines, it cannot be doubted that, for the
first time, an evidence-based ethos was energetically
applied to the diagnosis and management of IPF. How-
ever, it was telling that nothing useful was said about that
great desideratum, multidisciplinary diagnosis. Certainly,
the phrase ‘multidisciplinary diagnosis’ makes cameo ap-
pearances from time to time, but what is described in the
document as multidisciplinary diagnosis is unrecognisable
to most practising clinicians, radiologists and histopathol-
ogists. The casual reader, focusing on tables and key
conclusions, might be excused for imagining that the
process of multidisciplinary diagnosis consists of amal-
gamating a histological grade and a high-resolution com-
puter tomography (HRCT) category, each reached in
isolation, providing a definition of possible, probable or
definite IPF. In this model, the clinician has no particular
role, apart from the exclusion of a primary cause of
pulmonary fibrosis. The problem, here, is that diagno-
sis for trial purposes, enshrined in the 2011 guideline,
differs radically from enlightened multidisciplinary
diagnosis.
In treatment trials, it is essential that diagnosis is
rigorous and standardised in order to minimise diagnos-
tic variation between treatment arms. In essence, this
means the use of simplistic clinical exclusion criteria and
HRCT data, and a requirement for a diagnostic surgical
biopsy when HRCT appearances are inconclusive. Rigid
diagnostic criteria require the exclusion of all information
not available in all patients. Observed disease behaviour,
on and off therapy, does not feature as a possible influence
on the likelihood of IPF in the ATS/ERS/JRS/ALAT 2011
guidelines because, at enrolment into a trial protocol,
observations of disease behaviour are not always available.
Bronchoalveolar lavage is not a part of the diagnostic
algorithm in all countries and therefore it was relegated to
an undefined ‘weak negative’ role in the ATS/ERS/JRS/
ALAT 2011 guidelines. This is relevant because, in clinical
practice, hypersensitivity pneumonitis exposures are not,
in reality, a simple ‘present/absent’ dichotomy. Often,
there is real difficulty in assigning significance to exposure.
The whole question of what constitutes occult connective
tissue disease is too complex to summarise concisely, but
frequently contributes to the warp and weft of multidis-
ciplinary diagnosis.
For trial purposes, diagnosis must necessarily be ‘dumbed
down’. Multidisciplinary diagnosis is a different matter
altogether. Trial diagnostic criteria require the consider-
ation only of data standardisable in all patients. By contrast,
multidisciplinary diagnosis requires the consideration of
all potentially relevant information in every individual pa-
tient. Trial diagnostic criteria confine expert judgement to
the isolated views of the radiologist and histopathologist,
with subtle clinical interpretation disallowed. Multidiscip-
linary diagnosis consists of debate and the integration and
reconciliation of a huge amount of ancillary clinical infor-
mation. It is sometimes supposed that the major value of
multidisciplinary diagnosis consists simply of broadening
expertise. However, it can also be argued that the true
value of a multidisciplinary team lies in bringing together
trained minds accustomed to civilised disagreement and
the scrutiny of logic and common sense. Above all, the
use of logic, common sense and review of all data (which
differs widely in its completeness in every patient) cannot
be validated using an evidence-based approach in which
inflexible diagnostic criteria are required.
Conclusions
With the use of a multidisciplinary approach, a diagnosis
of IPF can often be made, based on very high probability,
in patients who lie outside guideline criteria. Anti-
fibrotic therapy in this large patient subgroup can be in-
stituted with the same confidence as in ‘definite IPF’, as
defined in the 2011 guidelines. In other cases, in which
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IPF is merely the most likely of several possible diagno-
ses, an eventual working diagnosis of IPF and the intro-
duction of anti-fibrotic therapy can be justified by
subsequent disease progression despite immunomodula-
tory therapy. In this area, medicine is as much an art as
a science. The evidence-base apparatchik need not
despair – the time will come for the multidisciplinary
approach in IPF to be subjected to evidence-based evalu-
ation. The accuracy of a flexible approach to diagnosis,
based on the integration of clinical reasoning and mor-
phologic (CT and pathology) pattern recognition, can be
examined against subsequent natural history and treat-
ment course, given that the value of making a diagnosis
is in the provision of this information. However, the
answer does not lie in recreating new rigid diagnostic
criteria for IPF to the detriment of clinical reasoning. As
Thoreau, father of the pragmatic philosophy movement
once said, “any fool can make a rule and any fool will
mind it”.
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